Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 3/20 | 0.50 |
| ▸ | CNR2 | P34972 | 9/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5455250 | 0.91 | CNR2 (0.48) | CNR1CNR2P2RX7PLK1 | |
| SCHEMBL5462921 | 0.90 | SMN1; SMN2 (0.55) | KMT2ACNR1CNR2P2RX7PLK1 | |
| SCHEMBL5451287 | 0.88 | L3MBTL1 (0.54) | KMT2AL3MBTL1CNR1CNR2P2RX7 | |
| SCHEMBL14411259 | 0.88 | SMN1; SMN2 (0.55) | KMT2ACNR1CNR2P2RX7PLK1 | |
| SCHEMBL5455285 | 0.86 | KDM4E (0.52) | CNR1CNR2P2RX7PLK1 | |
| SCHEMBL14464406 | 0.81 | CNR2 (0.42) | CNR1CNR2P2RX7 | |
| SCHEMBL5453464 | 0.80 | ADRA1D (0.52) | KMT2ACNR2P2RX7MEN1PLK1 | |
| SCHEMBL5453540 | 0.79 | CNR2 (0.46) | CNR1CNR2 | |
| SCHEMBL5453565 | 0.79 | ALDH1A1 (0.42) | CNR1CNR2P2RX7PLK1 | |
| SCHEMBL5446506 | 0.79 | SMN1; SMN2 (0.42) | KMT2ACNR1CNR2P2RX7PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | KMT2A 4056/4885L3MBTL1 4494/4885CNR1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.